四年亏掉近15亿元,“卖老鼠”的百奥赛图IPO被中止

Ofweek光电信息网
25 Apr

百奥赛图欲为国内基因编辑领域首家“A+H”上市公司的梦想,暂时落空了。2023年6月,头顶“基因编辑第一股”、登陆港交所资本市场不到一年的百奥赛图,在上交所了提交招股书,计划在A股科创板上市。7月,百奥赛图被问询。之后的推进极为缓慢。直到2025年3月31日,百奥赛图的IPO状态变更为“中止”,需要重新更新。科创板IPO被“中止”,将百奥赛图连年亏损、实控人沈月雷博士近9000万元的债务、高管薪酬...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10